 |
|
|
| |
Pharmacokinetics of Hepatitis C Virus Protease Inhibitor MK-5172 in Volunteers With Mild and Moderate Hepatic Impairment
|
| |
| |
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
L Caro1, WW Yeh1, M Ho1, N Uemura1, Z Guo1, J Talaty1, C Reitmann1, IP Fraser1, A Testro2, P Angus2, T Marbury3, E Gane4, JR Butterton1
1Merck & Co., Inc., Whitehouse Station, NJ, USA; 2Centre for Clinical Studies, Melborne, VIC, Australia; 3Orlando Clinical Research Center, Orlando, FL, USA,4Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
